Published March 25, 2015 | Version v1
Journal article Metadata-only

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance

Creators

  • 1. Center for Oncological Research Antwerp, University of Antwerp, Universiteitsplein 1, Wilrijk 2610 (Belgium)
  • 2. Molecular Pathology Unit, Pathology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650 (Belgium)
  • 3. Department of Oncology, Clínica Universidad de Navarra, Pamplona 31008 (Spain)
  • 4. Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650 (Belgium)
  • 5. Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, Pembroke Pines, FL 33024 (United States)
  • 6. 4Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, Pembroke Pines, FL 33024 (United States)

Description

In the last decade, the tyrosine kinase receptor cMET, together with its ligand hepatocyte growth factor (HGF), has become a target in non-small cell lung cancer (NSCLC). Signalization via cMET stimulates several oncological processes amongst which are cell motility, invasion and metastasis. It also confers resistance against several currently used targeted therapies, e.g., epidermal growth factor receptor (EGFR) inhibitors. In this review, we will discuss the basic structure of cMET and the most important signaling pathways. We will also look into aberrations in the signaling and the effects thereof in cancer growth, with the focus on NSCLC. Finally, we will discuss the role of cMET as resistance mechanism

Availability note (English)

Available from http://dx.doi.org/10.3390/cancers7020556; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491670

Additional details

Identifiers

URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491670;
DOI
10.3390/cancers7020556;

Publishing Information

Journal Title
Cancers (Basel)
Journal Volume
7
Journal Issue
2
Journal Page Range
p. 556-573
ISSN
2072-6694

INIS

Country of Publication
Switzerland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47006818
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
GROWTH FACTORS; HEAD; HYDRA; NEOPLASMS; RECEPTORS; THERAPY
Descriptors DEC
ANIMALS; BODY; CNIDARIA; COELENTERATA; DISEASES; INVERTEBRATES; MEDICINE; MEMBRANE PROTEINS; MITOGENS; ORGANIC COMPOUNDS; PROTEINS

Optional Information

Copyright
Copyright (c) 2015 by the authors
Notes
PMCID: PMC4491670; PMID: 25815459; PUBLISHER-ID: cancers-07-00556; OAI: oai:pubmedcentral.nih.gov:4491670; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).